---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105487"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:50:24.327898+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR

## Summary
- Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.
- Cash $661.1M; runway into 1H'28; BLA submission for cretostimogene planned in Q4'25.
- Jury unanimously ruled CG owes no future royalties to ANI, eliminating 5% commercial royalty.
- BOND-003 Cohort C: 75.5% CR at any time; 12-mo CR 50.7%, 24-mo CR 42.3% (K-M); median DOR 28 mo.
- CORE-008 Cohort CX (cretostimogene + gemcitabine) initiated in HR BCG-exposed NMIBC.

## SEC filing metadata
- accession: 0000950170-25-105487
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/0000950170-25-105487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/ck0001991792-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105487
- JSON: https://secwatch.observer/filing/0000950170-25-105487.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.